Check Out Stefan Windisch's LinkedIn Stats (Last 30 Days)

Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter - Group sales grew by 6% at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions. - Pharmaceuticals Division sales rose by 8% (9% in CHF) on continued strong demand for a broad range of our medicines; top growth drivers were Phesgo (breast cancer), Vabysmo (severe eye diseases), Xolair (allergies) and Hemlibra (haemophilia A). - Diagnostics Division sales remained stable with high demand across products and regions offsetting the impact of the recent healthcare pricing reforms in China. - Outlook for 2025 confirmed

🚀 We’re Hiring! Join Roche as an InHouse Bank Specialist! 💼✨ Our Treasury team is growing! We’re looking for talented InHouse Bank Specialists (temporary, 12-month contract with extension potential) to drive innovation and efficiency in our payments and settlements processes. In this role, you'll work on exciting projects like ISO20022 implementation, innovative data utilization, advanced data analytics, and InHouse Bank process automation, while supporting daily operations and cross-functional initiatives. 🔹 Do you have SAP (InHouse Cash, APM, S4/Hana) expertise? 🔹 Passionate about digital transformation in Treasury? 🔹 Thrive in a dynamic, global finance environment? If this sounds like you, let’s connect! Apply now and play a key role in shaping the future of Treasury at Roche! 🔗  #Hiring #RocheTreasury #FinanceJobs #DigitalTransformation #Payments Roche https://lnkd.in/dVfS4PHz

Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth => Group sales grew by 7% at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics. => Excluding COVID-19, Group sales increased by 9%. COVID-19 will not adversely impact our results from 2025 onwards. => The fourth quarter was the third consecutive quarter of 9% sales growth, highlighting the very positive momentum. => Pharmaceuticals Division sales rose by 8% (excluding COVID-19 medicine: 9%) on growing demand for newer medicines; top growth drivers were Vabysmo (severe eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis) and Hemlibra (haemophilia A). => Diagnostics Division sales increased by 4%, reflecting the base effect of the sales of COVID-19 tests in the prior-year period; strong momentum in the Diagnostics Division’s base business continued with an increase of 8% due to higher demand for immunodiagnostic, pathology and molecular solutions. => Core operating profit grew by 14% (8% in CHF), driven by higher sales, improved gross margin and effective cost management; core earnings per share rose by 7% (1% in CHF). Core earnings per share excluding the impact of the resolution of tax disputes in 2023 rose by 12%, exceeding the guidance for 2024. => IFRS net income decreased by 19% (26% in CHF), mainly due to impairment charges to goodwill related to Flatiron Health and Spark Therapeutics. => Operating free cash flow increased by 34% (CER) to CHF 20.1 billion. #DoingNowWhatPatientsNeedNext

Roche ’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months => Group sales grew by 6% at constant exchange rates (CER) (2% in CHF) in the first nine months, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8% In the third quarter, Group sales rose by 9% (6% in CHF), as they did in the second quarter => Pharmaceuticals Division sales rose by 7% in the first nine months; the strong growth of 9% in the base business was driven by continued high demand for our newer medicines to treat severe diseases; Vabysmo (serious eye diseases), Phesgo (breast cancer) and Ocrevus (multiple sclerosis) were major growth drivers => Diagnostics Division sales increased by 5% in the first nine months, while the base business grew by 8% due to higher demand for immunodiagnostic, pathology and molecular solutions

At the EuroFinance conference in Copenhagen, Roche Treasury was honored to receive the award for "Specially Commended for Industry-Wide Digital Transformation." Curious to learn more about the solution we implemented with Swift, tested across several of our partner banks? Check out the article below! Economist Impact #RocheTreasury #Swift  #EuroFinanceIntl #EuroFinanceAwards #TreasuryExcellence #DigitalTransformation #Innovation #Roche #Finance

Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised => Group sales were up by 5% at constant exchange rates (CER) (stable in CHF) in the first half, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8% => Group sales growth accelerated to 9% (7% in CHF) in the second quarter as the decline in COVID-19-related sales no longer had an impact on overall sales => Pharmaceuticals Division sales rose by 5% in the first half; strong growth of 8% in the base business excluding COVID-19 effect was driven by continued high demand for our newer medicines to treat severe diseases; eye medicine Vabysmo was again the major growth driver => Diagnostics Division sales rose by 5%, while growth in the base business, which excludes the impact of COVID-19 sales, was 9% due to higher demand for immunodiagnostic products => Core operating profit increased by 11% (4% in CHF), core earnings per share grew by 9% (1% in CHF) and IFRS net income was down by 4% More details: